We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new and old optimized drugs are central to any control strategy and the fastest route to tuberculosis elimination.
Latest news
PanACEA-SUDOCU-01 publication in the Lancet Infectious Diseases 08 July 2025
PanACEA-SUDOCU-01 was a phase 2b clinical trial conducted at four locations in Tanzania and South Africa. The innovative study design allowed administration of a novel backbone of bedaquiline–delamanid–moxifloxacin alone and together with four sutezolid doses (ranging from 600 mg once daily to 800 mg twice daily) to 75 adults with drug-susceptible pulmonary tuberculosis for 12…
Read more PanACEA-SUDOCU-01 publication in the Lancet Infectious Diseases 08 July 2025
Podcast on TB drug development with Lilian Tina Minja and Norbert Heinrich for the Lancet
The Lancet Infectious Diseases in conversation with Lilian Tina Minja and Norbert Heinrich on TB drug development Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for…
Read more Podcast on TB drug development with Lilian Tina Minja and Norbert Heinrich for the Lancet
Staggered dosing of rifampicin using to minimise tolerability problems and maximize efficacy
PanACEA team together with collaborators at Uppsala University recently published a model-based study further elucidating how to optimally dose rifampicin. The work suggest that a staggered approach, starting a bit lower and then increasing doses, may improve the tolerability for patients and thereby enable the higher doses which we demonstrated earlier is beneficial in terms…
SUDOCU headline results presented at CROI
On Tuesday 20 February 2023 our PanACEA colleague Dr Norbert Heinrich presented the headline-results from the PanACEA SUDOCU study at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle – the largest and most important conference on HIV and related conditions such as tuberculosis. SUDOCU investigated safety and efficacy of varying doses of…
PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022
Finally, after 2 years due to COVID-19, the PanACEA and SimpliciTB family were reunited in Malawi, hosted by Dr Marriott Nliwasa, Kamuzu University of Health Sciences at Makokola Retreat, Mangochi. The hospitality and organisation of all of the teams made it a very successful and enjoyable meeting. PanACEA The first day started with a variety…
Read more PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022